Benzinga | Aug 12, 2020 07:18AM EDT

Truist Securities Maintains Buy on Catalyst Pharmaceuticals, Lowers Price Target to $8

Truist Securities maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and lowers the price target from $10 to $8.